Apotea AB (publ) (CHIX:APOTES) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:APOTES Apotea AB (publ) CHIX:APOTES
18 GF Score
Price kr65.20
! 1 Warning Sign
View Full Analysis

What is Apotea AB (publ) 5-Year EBITDA Growth Rate?

Apotea AB (publ) CHIX:APOTES 18 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates CHIX:APOTES with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

Apotea AB (publ)'s EBITDA per Share for the three months ended in Jun. 2026 was kr1.52.

During the past 12 months, Apotea AB (publ)'s average EBITDA Per Share Growth Rate was 13.50% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 64.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Apotea AB (publ) was 64.20% per year. The lowest was 30.10% per year. And the median was 47.15% per year.

Apotea AB (publ)  (CHIX:APOTEs) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Apotea AB (publ) 5-Year EBITDA Growth Rate Related Terms

Apotea AB (publ) 5-Year EBITDA Growth Rate Competitor Comparison

For the Pharmaceutical Retailers subindustry, Apotea AB (publ)'s 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apotea AB (publ) 5-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Apotea AB (publ)'s 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Apotea AB (publ)'s 5-Year EBITDA Growth Rate falls into.


CHIX:APOTES
18GF Score
Apotea AB (publ) CHIX:APOTES
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apotea AB (publ) 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Apotea AB (publ) (CHIX:APOTES) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Apotea AB (publ) and its competitors.
Is Apotea AB (publ)'s 5-Year EBITDA Growth Rate too high?
Apotea AB (publ)'s current 5-Year EBITDA Growth Rate is 0.00%. Overall, Apotea AB (publ) has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Apotea AB (publ)'s 5-Year EBITDA Growth Rate compare to competitors?
Apotea AB (publ)'s 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
A good 5-Year EBITDA Growth Rate depends on the Healthcare Providers & Services industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Apotea AB (publ) and its competitors. Apotea AB (publ)'s current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apotea AB (publ) stock overvalued right now?
Apotea AB (publ) (CHIX:APOTES) has a current 5-Year EBITDA Growth Rate of 0.00%. The current 5-Year EBITDA Growth Rate is 0.00%. Apotea AB (publ)'s overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Apotea AB (publ) (CHIX:APOTES), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apotea AB (publ) Business Description

Other Exchanges APOTEA:SwedenV30:Germany
Address Sveavagen 168, Stockholm, SWE, 11346
Apotea AB (publ) is engaged in the online pharmacy with fast deliveries, good prices and a large selection. Its vision is to be tomorrow's pharmacy by constantly facilitating and simplifying for the customer.
18GF Score

Get the complete analysis for CHIX:APOTES

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr65.20
Price